Browse > Article
http://dx.doi.org/10.5352/JLS.2013.23.10.1216

Inhibition of Oncogenes Affects the Expression of NKG2D Ligands in Cancer Cells  

Heo, Woong (Department of Biochemistry, Pusan National University School of Medicine)
Lee, Young Shin (Department of Biochemistry, Pusan National University School of Medicine)
Bae, Jaeho (Department of Biochemistry, Pusan National University School of Medicine)
Publication Information
Journal of Life Science / v.23, no.10, 2013 , pp. 1216-1222 More about this Journal
Abstract
NK cells are lymphoid immune cells that participate in innate immunity to protect against foreign pathogens and transforming cells. It is known that the activity of NK cells is regulated by a balance between activating and inhibitory signals rather than specific antigens. One important activating signal is mediated by the NKG2D receptor, which recognizes NKG2D ligands on cancer cells. Therefore, tumor cells that express sufficient amounts of NKG2D ligands could be eliminated by NKD2D+ cells, including NK cells. Oncogenes drive tumor cells to apoptosis resistant and uncontrolled proliferation by altered expression of many critical genes. Therefore, the expression of NKG2D ligands may be affected by oncogenes. This study focused on increasing the susceptibility of cancer cells to NK cells by regulating the expression of NKG2D ligands influenced by three oncogenes: k-ras, wnt, and c-myc. We demonstrated that inhibition of k-ras and c-myc increased the expression of NKG2D ligands and enhanced the susceptibility of cancer cells to NK cells. On the contrary, inhibition of the wnt pathway decreased MICA and ULBP1 transcripts. Although the decreased transcription of NKG2D ligands by inhibition of the wnt pathway, surface proteins of NKG2D ligands were not changed, and the susceptibility of HCT-116 cells was unaffected. The results demonstrate that the transcription of NKG2D ligands are regulated deferentially by the k-ras, c-myc, and wnt pathways and that the cytotoxicity of NK cells solely depends on the amount of surface NKG2D ligands.
Keywords
NK cells; NKG2D ligands; oncogenes;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bae, J. H., Kim, J. Y., Kim, M. J., Chang, S. H., Park, Y. S., Son, C. H., Park, S. J., Chung, J. S., Lee, E. Y., Kim, S. H. and Kang, C. D. 2010. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. J Immunother 33, 391-401.   DOI
2 Bae, J. H., Kim, S. J., Kim, M. J., Oh, S. O., Chung, J. S., Kim, S. H. and Kang, C. D. 2012. Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci 103, 7-16.   DOI   ScienceOn
3 Campoli, M. and Ferrone, S. 2008. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 72, 321-334.   DOI   ScienceOn
4 Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991-998.   DOI   ScienceOn
5 Fuertes, M. B., Girart, M. V., Molinero, L. L., Domaica, C. I., Rossi, L. E., Barrio, M. M., Mordoh, J., Rabinovich, G. A. and Zwirner, N. W. 2008. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 180, 4606-4614.   DOI
6 Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., Edkins, S., O'Meara, S., Vastrik, I., Schmidt, E. E., Avis, T., Barthorpe, S., Bhamra, G., Buck, G., Choudhury, B., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Jenkinson, A., Jones, D., Menzies, A., Mironenko, T., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Cahill, D. P., Louis, D. N., Goldstraw, P., Nicholson, A. G., Brasseur, F., Looijenga, L., Weber, B. L., Chiew, Y. E., DeFazio, A., Greaves, M. F., Green, A. R., Campbell, P., Birney, E., Easton, D. F., Chenevix-Trench, G., Tan, M. H., Khoo, S. K., Teh, B. T., Yuen, S. T., Leung, S. Y., Wooster, R., Futreal, P. A. and Stratton, M. R. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158.   DOI   ScienceOn
7 Mazieres, J., He, B., You, L., Xu, Z. and Jablons, D. M. 2005. Wnt signaling in lung cancer. Cancer Lett 222, 1-10.   DOI   ScienceOn
8 Minamoto, T., Mai, M. and Ronai, Z. 2000. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. Cancer Detect Prev 24, 1-12.
9 Molinero, L. L., Domaica, C. I., Fuertes, M. B., Girart, M. V., Rossi, L. E. and Zwirner, N. W. 2006. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol 67, 170-182.   DOI   ScienceOn
10 Nesbit, C. E., Tersak, J. M. and Prochownik, E. V. 1999. MYC oncogenes and human neoplastic disease. Oncogene 18, 3004-3016.   DOI   ScienceOn
11 Shimizu, H., Julius, M. A., Giarre, M., Zheng, Z., Brown, A. M. and Kitajewski, J. 1997. Transformation by Wnt family proteins correlates with regulation of beta-catenin. Cell Growth Differ 8, 1349-1358.
12 Park, S. W., Bae, J. H., Kim, S. D., Son, Y. O., Kim, J. Y., Park, H. J., Lee, C. H., Park, D. Y., Lee, M. K., Chung, B. S., Kim, S. H. and Kang, C. D. 2007. Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR. Cancer Invest 25, 299-307.   DOI   ScienceOn
13 Rubinfeld, B., Souza, B., Albert, I., Muller, O., Chamberlain, S. H., Masiarz, F. R., Munemitsu, S. and Polakis, P. 1993. Association of the APC gene product with beta-catenin. Science 262, 1731-1734.   DOI   ScienceOn
14 Salih, J., Hilpert, J., Placke, T., Grunebach, F., Steinle, A., Salih, H. R. and Krusch, M. 2010. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 127, 2119-2128.   DOI   ScienceOn
15 Smyth, M. J., Hayakawa, Y., Takeda, K. and Yagita, H. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2, 850-861.   DOI   ScienceOn
16 Takebe, N., Harris, P. J., Warren, R. Q. and Ivy, S. P. 2011. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8, 97-106.   DOI
17 Van Scoyk, M., Randall, J., Sergew, A., Williams, L. M., Tennis, M. and Winn, R. A. 2008. Wnt signaling pathway and lung disease. Transl Res 151, 175-180.   DOI   ScienceOn
18 Vita, M. and Henriksson, M. 2006. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16, 318-330.   DOI   ScienceOn